B3GAT2 and malignant colon neoplasm: Glucuronidation has been considered as a potential target of anticancer drug resistance including for colon cancer [21, 40], but mechanisms for regulating the pathway have been unclear and the large number of UDP-glucuronosyltransferases (UGTs) has made them poor candidates for targeting the pathway.